Effect of spermine on lipid profile and HDL functionality in the streptozotocin-induced diabetic rat model.
This study aimed to investigate the effect of spermine (Spm) as a chemical chaperone and glycation inhibitor on the lipid profile and HDL functionality in the short- and long-term treatment of the STZ-induced diabetic rats. Male Wistar rats were divided into 4 groups (control, n=7; diabetic, n=9). Two groups (named 2 and 3) were injected intraperitoneally with streptozotocin. Control rats (named 1 and 4) were injected with vehicle alone. The treatment of diabetic and control animals (groups 3 and 4) with 60 micromol/l of Spm in drinking water was begun. The study continued up to the end of the fifth month. The serum glucose and insulin level, AGE formation, lipid profile, paraoxonase 1 (PON1), and lecithin: cholesterol acyl transferase (LCAT) activities were measured. Significantly lower plasma PON1, and LCAT activities and higher serum AGE, TG, TC and LDL-c, and lower HDL-c were seen in diabetic rats as compared to control groups (P<0.01). The increased AGE, TG, TC and LDL-c levels in diabetic groups decreased gradually after receiving Spm. In addition, due to Spm administration, an increase in the HDL-c level was observed after the first month of the experiment (P<0.01). The increase in the PON1 and LCAT activities in the diabetic group that received Spm was significant after the second and the forth month of the experiment, P<0.02 and P<0.05, respectively. In conclusion, spermine administration attenuated the changed parameters to near normal values in diabetic rats. Spermine, despite a lack of significant changes on glucose metabolism and insulin secretion, was found to improve diabetes complications.
Jafarnejad
A
A
Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, P.O. Box: 14115-111, Tehran, Iran.
Bathaie
S Z
SZ
Nakhjavani
M
M
Hassan
M Z
MZ
D000284:Administration, Oral; D000818:Animals; D043303:Aryldialkylphosphatase / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy*; D017127:Glycation End Products, Advanced / Q000097:blood; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D050356:Lipid Metabolism; D008075:Lipoproteins, HDL / Q000097:blood*; D008297:Male; D007862:Phosphatidylcholine-Sterol O-Acyltransferase / Q000097:blood; D051381:Rats; D017208:Rats, Wistar; D013096:Spermine / Q000627:therapeutic use*
D001786:Blood Glucose; D017127:Glycation End Products, Advanced; D000960:Hypolipidemic Agents; D007328:Insulin; D008075:Lipoproteins, HDL; D013096:Spermine; D007862:Phosphatidylcholine-Sterol O-Acyltransferase; D043303:Aryldialkylphosphatase